The purpose of this study was to describe 18F-FDG uptake across a spectrum of pediatric brain tumors and correlate 18F-FDG PET with MR imaging variables, progression-free survival (PFS), and'/> 18F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium
首页> 外文期刊>The Journal of Nuclear Medicine >18F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium
【24h】

18F-FDG PET and MR Imaging Associations Across a Spectrum of Pediatric Brain Tumors: A Report from the Pediatric Brain Tumor Consortium

机译:小儿脑肿瘤谱中的18F-FDG PET和MR成像关联:小儿脑肿瘤联盟的报告

获取原文
           

摘要

id="p-2">The purpose of this study was to describe 18F-FDG uptake across a spectrum of pediatric brain tumors and correlate 18F-FDG PET with MR imaging variables, progression-free survival (PFS), and overall survival (OS). >Methods: A retrospective analysis was conducted of children enrolled in phase I/II clinical trials through the Pediatric Brain Tumor Consortium from August 2000 to June 2010. PET variables were summarized within diagnostic categories using descriptive statistics. Associations of PET with MR imaging variables and PFS and OS by tumor types were evaluated. >Results: Baseline 18F-FDG PET was available in 203 children; 66 had newly diagnosed brain tumors, and 137 had recurrent/refractory brain tumors before enrolling in a Pediatric Brain Tumor Consortium trial. MR imaging was performed within 2 wk of PET and before therapy in all cases. The 18F-FDG uptake pattern and MR imaging contrast enhancement (CE) varied by tumor type. On average, glioblastoma multiforme and medulloblastoma had uniform, intense uptake throughout the tumor, whereas brain stem gliomas (BSGs) had low uptake in less than 50% of the tumor and ependymoma had low uptake throughout the tumor. For newly diagnosed BSG, correlation of 18F-FDG uptake with CE portended reduced OS (P = 0.032); in refractory/recurrent BSG, lack of correlation between 18F-FDG uptake and CE suggested decreased PFS (P = 0.023). In newly diagnosed BSG for which more than 50% of the tumor had 18F-FDG uptake, there was a suggestion of lower apparent diffusion coefficient (P = 0.061) and decreased PFS (P = 0.065). >Conclusion: 18F-FDG PET and MR imaging showed a spectrum of patterns depending on tumor type. In newly diagnosed BSG, the correlation of 18F-FDG uptake and CE suggested decreased OS, likely related to more aggressive disease. When more than 50% of the tumor had 18F-FDG uptake, the apparent diffusion coefficient was lower, consistent with increased cellularity. In refractory/recurrent BSG, poor correlation between 18F-FDG uptake and CE was associated with decreased PFS, which may reflect concurrent tissue breakdown at sites of treated disease and development of new sites of 18F-FDG-avid malignancy.
机译:id =“ p-2”>本研究的目的是描述整个儿科脑肿瘤中 18 F-FDG的摄取,并与 18 F-FDG相关具有MR成像变量,无进展生存期(PFS)和总体生存期(OS)的PET。 >方法:回顾性分析了2000年8月至2010年6月间通过小儿脑肿瘤联合会参加I / II期临床试验的儿童。PET变量使用描述性统计资料总结在诊断类别内。评价了PET与MR成像变量以及肿瘤类型对PFS和OS的关系。 >结果:203名儿童可获得基线 18 F-FDG PET;在参加小儿脑肿瘤联盟试验之前,有66例新诊断出脑肿瘤,而137例患有复发/难治性脑肿瘤。在所有情况下,均在PET的2周内和治疗前进行MR成像。 18 F-FDG摄取模式和MR成像对比增强(CE)因肿瘤类型而异。平均而言,多形性胶质母细胞瘤和髓母细胞瘤在整个肿瘤中具有均匀,强烈的摄取,而脑干神经胶质瘤(BSG)在少于50%的肿瘤中具有低摄取,而室管膜瘤在整个肿瘤中具有低摄取。对于新诊断的BSG, 18 F-FDG摄取与CE的相关性预示着OS的降低( P = 0.032);在难治性/复发性BSG中, 18 F-FDG摄取与CE之间缺乏相关性,提示PFS降低( P = 0.023)。在新诊断出的BSG中,有超过50%的肿瘤摄取了 18 F-FDG,这表明表观扩散系数较低( P = 0.061)并降低了PFS( P = 0.065)。 >结论: 18 F-FDG PET和MR成像显示了一系列取决于肿瘤类型的模式。在新诊断的BSG中, 18 F-FDG摄取与CE的相关性提示OS降低,可能与更具侵略性的疾病有关。当超过50%的肿瘤摄取 18 F-FDG时,表观扩散系数较低,与细胞增多有关。在难治性/复发性BSG中, 18 F-FDG摄入量与CE之间的相关性差与PFS降低有关,这可能反映了在治疗疾病部位同时发生组织分解和 18新部位的发展 F-FDG-avid恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号